Long-term survival in SCLC after treatment with paclitaxel, carboplatin and etoposide--a phase II study (Q44260334)

1 December 2017

title

Long-term survival in SCLC after treatment with paclitaxel, carboplatin and etoposide--a phase II study (English)

1 reference

lung small cell carcinoma

1 December 2017

main subject

1 reference

1 reference

1 reference

Martin Reck

1

1 reference

1 December 2017

Urzula Jagos

2

1 reference

1 December 2017

Franziska Grunwald

3

1 reference

1 December 2017

Eckhard Kaukel

4

1 reference

1 December 2017

Gabriele Koschel

5

1 reference

1 December 2017

Joachim von Pawel

6

1 reference

1 December 2017

Sybill Hessler

7

1 reference

1 December 2017

Ulrich Gatzemeier

8

1 reference

1 December 2017

publication date

1 January 2003

1 reference

1 December 2017

1 reference

1 December 2017

volume

39

1 reference

1 December 2017

issue

1

1 reference

1 December 2017

page(s)

63-69

1 reference

Alkylating agents in bronchogenic carcinoma

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900383-5

7 January 2021

A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900383-5

7 January 2021

Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900383-5

7 January 2021

Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900383-5

7 January 2021

Carboplatin and etoposide in extensive small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900383-5

7 January 2021

Is carboplatin and oral etoposide an effective and feasible regimen in patients with small cell lung cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900383-5

7 January 2021

Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900383-5

7 January 2021

Superiority of high-dose platinum (cisplatin and carboplatin) compared to carboplatin alone in combination chemotherapy for small-cell lung carcinoma: a prospective randomised trial of 280 consecutive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900383-5

7 January 2021

Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900383-5

7 January 2021

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900383-5

7 January 2021

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900383-5

7 January 2021

Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900383-5

7 January 2021

Prolonged administration of low-daily-dose etoposide: a superior dosing schedule?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900383-5

7 January 2021

Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900383-5

7 January 2021

Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900383-5

7 January 2021

Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900383-5

7 January 2021

Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900383-5

7 January 2021

Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900383-5

7 January 2021

Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900383-5

7 January 2021

Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900383-5

7 January 2021

Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900383-5

7 January 2021

10.1016/S0169-5002(02)00383-5

Identifiers

DOI

1 reference

1 December 2017

1 reference